



Conference Cochairs:

Andrew M. Lowy, UC San Diego, La Jolla, California Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, Michigan Robert H. Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

[R] Remote presentation

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

TUESDAY, SEPTEMBER 13	
6:00 p.m7:25 p.m.	Welcome and Keynote Lectures
Grand Liberty Ballroom	
6:00 p.m6:10 p.m.	Welcome from Cochairs Andrew M. Lowy, UC San Diego, La Jolla, California
6:10 p.m6:15 p.m.	Welcome from Lead Supporter Andrew Rakeman, Lustgarten Foundation, Woodbury, New York
6:15 p.m6:45 p.m.	Rising Star Keynote [CME Eligible] Truncated O-glycosylation in pancreatic cancer Avery D. Posey Jr., University of Pennsylvania, Philadelphia, Pennsylvania
6:45 p.m7:25 p.m.	Opening Keynote [CME Eligible] Contextual determinants of pancreatic tumorigenesis Dafna Bar-Sagi, NYU Langone Medical Center, New York, New York
7:30 pm-9:00 pm Back Bay Ballroom	Poster Session A / Opening Reception
WEDNESDAY, SEPTEMBER 14 7:00 a.m.–8:00 a.m. Back Bay Ballroom	Breakfast Round Tables How to Get a Paper Published
	Robert Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania
	How to Write a Grant Marina Pasca di Magliano, University of Michigan Medical School, Ann Arbor, Michigan





	 Howard C. Crawford, Henry Ford Pancreatic Cancer Center, Detroit, Michigan Starting Your Lab Katelyn T. Byrne, Oregon Health & Science University, Portland, Oregon Yuliya Pylayeva-Gupta, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina Getting Tenure Edna Cukierman, Fox Chase Cancer Center, Philadelphia, Pennsylvania Balancing Clinical and Research Life Andrew M. Lowy, UC San Diego, La Jolla, California Diane Simeone, New York University, New York, New York
8:00 a.m.–10:00 a.m.	Plenary Session 1 Disparities and Health Equity [CME Eligible]
Grand Liberty Ballroom Session Chair: Maria Elena Mar	rtinez, UCSD Moores Cancer Center, La Jolla, California
8:00 a.m8:30 a.m.	Advocating for health equity in pancreatic cancer
0.00 d.1110.50 d.111.	Karen Winkfield, Meharry-Vanderbilt Alliance, Nashville, Tennessee
8:30 a.m8:45 a.m.	Socioeconomic analysis and disparities in germline genetic testing for pancreatic cancer* Xianghui Zou, North Shore University Hospital & Long Island Jewish Medical Center, New Hyde Park, New York
8:45 a.m9:00 a.m.	Transcriptomic influences of racial disparities in Black patients with pancreatic neuroendocrine tumors* Brendon Herring, University of Alabama at Birmingham, Birmingham, Alabama
9:00 a.m9:15 a.m.	Race plays a role on the rate of transdifferentiation in human pancreatic acinar ductal metaplasia and its' drug response* Corey Perkins, University of Florida, Gainesville, Florida
9:15 a.m9:45 a.m.	System-level approaches to cancer care equity [R] Cleo A. Samuel-Ryals, Flatiron Health, New York, New York
9:45 a.m10:00 a.m.	Discussion
10:00 a.m10:30 a.m. Grand Liberty Fover	Break

Grand Liberty Foyer





10:30 a.m.–12:30 p.m.	Plenary Session 2 Bench to Bedside: The Science that Underpins Clinical Trials [CME Eligible]
Grand Liberty Ballroom	
•	New York University, New York, New York
10:30 a.m11:00 a.m.	Generating T cell responses against pancreatic cancer Katelyn T. Byrne, Oregon Health & Science University, Portland, Oregon
11:00 a.m11:30 a.m.	Were the mice right? Applying immunobiological insights from the lab to the treatment of patients with pancreatic cancer Robert Vonderheide, Penn Medicine Abramson Cancer Center, Philadelphia, Pennsylvania
11:30 a.m11:45 a.m.	Characterizing the effects of neoadjuvant therapy in PDAC* Amaya Pankaj, Mass General Cancer Center, Harvard Medical School Boston, Massachusetts
11:45 a.m12:00 p.m.	Primary results of PanCAN-SR1, a phase 1b study evaluating Gemcitabine, nab-Paclitaxel, Canakinumab, and Spartalizumab to target IL-1β and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis* Paul Oberstein, NYU Langone Health, New York, New York
12:00 p.m-12:15 p.m.	Initial results of a cohort of advanced pancreatic cancer patients in a phase 1b study of NGM120, a first-in-class anti-GDNF Family Receptor Alpha Like (GFRAL) antibody* Andrew Hendifar, Cedars-Sinai Medical Center, Los Angeles, California
12:15 p.m12:30 p.m.	Discussion
12:30 p.m.–2:00 p.m.	Lunch on Own
2:00 p.m.–4:15 p.m. Grand Liberty Ballroom Session Chair: Scott W. Lowe, N	Plenary Session 3 Tumor Plasticity and Drug Resistance [CME Eligible] Aemorial Sloan Kettering Cancer Center, New York, New York
2:00 p.m2:30 p.m.	How important is cell state in cancer? Alex K. Shalek, Massachusetts Institute of Technology, Cambridge, Massachusetts
2:30 p.m2:45 p.m.	Three-dimensional genomic analysis of human pancreatic intraepithelial neoplasia (PanIN) reveals striking multifocality and genetic heterogeneity* Alicia Braxton, Johns Hopkins Medical Institute, Baltimore, Maryland



An AACR Special Conference on **Pancreatic Cancer** September 13-16 | Sheraton Boston Hotel | Boston, MA



2:45 p.m3:00 p.m.	Overcoming PDAC T cell therapy barriers with CD47-targeted costimulatory fusion proteins* Shannon Oda, Seattle Children's Research Institute, University of Washington, Seattle, Washington
3:00 p.m3:15 p.m.	An epigenetic memory of inflammation controls context-dependent lineage plasticity in the pancreas* David Falvo, Weill Cornell Medicine, New York, New York
3:15 p.m3:35 p.m.	Single-cell sequencing elucidates the effects of chemotherapy on cancer cell heterogeneity and the tumor microenvironment of human pancreatic adenocarcinoma* Emily Kawaler, New York University Langone Health, New York, New York
3:30 p.m4:00 p.m.	The origins and function of copy number alterations in pancreas cancer Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, New York
4:00 p.m4:15 p.m.	Discussion
4:15 p.m6:00 p.m. Back Bay Ballroom	Poster Session B / Reception
THURSDAY, SEPTEMBER 15 7:00 a.m.–8:00 a.m. Back Bay Ballroom	Breakfast Roundtables
back bay balloon	How to Write a Grant
	Marina Pasca di Magliano, University of Michigan Medical
	School, Ann Arbor, Michigan
	Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina
	Collaborating with Industry (begins at 7:30 a.m.)
	Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New
	York, New York Starting Your Lab
	Howard C. Crawford, Henry Ford Pancreatic Cancer Center,
	Detroit, Michigan
	Balancing Clinical and Research Life
	Andrew M. Lowy, UC San Diego, La Jolla, California





Kimberly Perez, Dana-Farber Cancer Institute, Boston, Massachusetts

8:00 a.m.–10:00 a.m.	Plenary Session 4 Challenges in Treating Locally Advanced Pancreatic Cancer [CME Eligible]
Grand Liberty Ballroom	
•	UC San Diego, La Jolla, California
8:00 a.m8:20 a.m.	Total neoadjuvant therapy for pancreatic cancer: The role of radiation therapy
	Theodore S. Hong, Massachusetts General Hospital, Boston, Massachusetts
8:20 a.m8:35 a.m.	Proteomic profiling reveals subtype specific kinase expression in pancreatic cancer*
	Yi Xu, University of North Carolina, Chapel Hill, NC
8:35 a.m8:50 a.m.	Perioperative liver biopsy captures features of the liver pre-metastatic niche and predicts metastatic outcome after pancreatic cancer resection*
	Linda Bojmar, Cornell University, New York, New York
8:50 a.m9:20 a.m.	Meeting the challenge of pancreatic cancer
	Philip A. Philip, Henry Ford Cancer Center, Detroit, Michigan
9:20 a.m9:50 a.m.	Precision oncology approaches in pancreatic cancer
	Jen Jen Yeh, University of North Carolina, Chapel Hill, North Carolina

- 9:50 a.m.-10:00 a.m. Panel Discussion
- **10:00 a.m.–10:30 a.m.** Break Grand Liberty Foyer

10:30 a.m.–12:30 p.m.	Plenary Session 5 Prevention & Interception [CME Eligible]
Grand Liberty Ballroom	
Session Chair: Sapna Syngal, Da	na-Farber Cancer Institute, Boston, Massachusetts

10:30 a.m.-11:00 a.m. Intraductal papillary mucinous neoplasms of the pancreas, an opportunity to prevent pancreatic cancer Peter J. Allen, Duke University School of Medicine, Durham, North Carolina





11:00 a.m11:15 a.m.	High sensitive mutation detection in liquid biopsy with duodenal fluid captures genetic mutations associated with pancreatic carcinogenesis* Yusuk Ono, Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan
11:15 a.m11:30 a.m.	Evaluating circulating tumor DNA by targeted next generation sequencing as a biomarker in the treatment of localized pancreatic cancer* Dhavan Shah, Northwestern University, Chicago, Illinois
11:30 a.m1:45 a.m.	Excess dietary oleic acid primes the pancreas for cancer* Christian Ruiz, Yale University, New Haven, Connecticut
11:45 a.m-12:15 p.m.	Intercepting pancreatic cancer development with mutant KRAS- targeted immunotherapy Neeha Zaidi, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
12:15 p.m12:30 p.m.	Discussion
12:30 p.m.–2:00 p.m.	Lunch on Own
2:00 p.m.–4:00 p.m. Grand Liberty Ballroom Session Chair: Edna Cukierman,	Plenary Session 6 Tumor Microenvironment [CME Eligible] Fox Chase Cancer Center, Philadelphia, Pennsylvania
Grand Liberty Ballroom	
Grand Liberty Ballroom Session Chair: Edna Cukierman,	Fox Chase Cancer Center, Philadelphia, Pennsylvania Collagen cleavage controls PDAC metabolism and malignancy via a DDR1-NRF2 cascade and mitochondrial biogenesis
Grand Liberty Ballroom Session Chair: Edna Cukierman, 2:00 p.m2:30 p.m.	 Fox Chase Cancer Center, Philadelphia, Pennsylvania Collagen cleavage controls PDAC metabolism and malignancy via a DDR1-NRF2 cascade and mitochondrial biogenesis Michael Karin, UC San Diego, La Jolla, California Aging modulates the tumor microenvironment of pancreatic cancer* Joaquín Araos Henríquez, Cancer Research UK Cambridge Institute,





3:15 p.m3:45 p.m.	Breaking down the PDAC tumor microenvironment Rama Khokha, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada
3:45 p.m4:00 p.m.	Discussion
4:00 p.m6:00 p.m. Back Bay Ballroom	Poster Session C / Reception
FRIDAY, SEPTEMBER 16 7:00 a.m.–8:00 a.m. Back Bay Ballroom	Breakfast
8:00 a.m.–10:00 a.m. Grand Liberty Ballroom	Plenary Session 7: Immunobiology and Immunotherapy [CME Eligible]
Session Chair: Marina Pasca ai N	Magliano, University of Michigan Medical School, Ann Arbor, Michigan
8:00 a.m8:30 a.m.	Determinants of B cell fate and function in cancer Yuliya Pylayeva-Gupta, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
8:30 a.m8:45 a.m.	Mutant KRAS-specific T cell receptors directed against prevalent G12D and G12V variants exhibit potent cytotoxic activity and CD8 co- receptor independence* Adham Bear, University of Pennsylvania, Philadelphia, Pennsylvania
8:45 a.m9:00 a.m.	Cholinergic modulation of T lymphocytes in pancreatic adenocarcinoma* Ruth White, Columbia University Medical Center, New York, New York
9:00 a.m9:15 a.m.	CCR1 expression defines pancreatic tumor associated macrophages and drives their immunosuppressive properties* Yaqing Zhang, University of Michigan, Ann Arbor, Michigan
9:15 a.m-9:30 a.m.	IL-17/IL-17RA signaling in the pancreatic epithelium upregulates CXCL5 and B7-H4 to promote tumorigenesis* Le Li, UT MD Anderson Cancer Center, Houston, Texas
9:30 a.m10:00 a.m.	Discussion
10:00 a.m.–10:30 a.m. Grand Liberty Foyer	Break

An AACR Special Conference on

Pancreatic Cancer

September 13-16 | Sheraton Boston Hotel | Boston, MA

10:30 a.m.-12:15 p.m.Plenary Session 8 Metabolism and Microbiome [CME Eligible]





Grand Liberty Ballroom Session Chair: Florencia McAllister, UT MD Anderson Cancer Center, Houston, Texas

10:30 a.m11:00 a.m.	The role of vitamin D receptor agonists in the treatment of pancreatic adenocarcinoma Kimberly Perez, Dana-Farber Cancer Institute, Boston, Massachusetts
11:00 a.m11:15 a.m.	Targeting gemcitabine resistance in pancreatic cancer* Alica Beutel, University of California, Irvine, Irvine, California
11:15 a.m11:30 a.m.	Investigating lipid homeostasis in pancreatic ductal adenocarcinoma under tumor-like stress* Xu Han, University of Pennsylvania, Philadelphia, Pennsylvania
11:30 a.m-12:00 p.m.	ATP production in pancreas cancer and tumor infiltrating lymphocytes Joshua D. Rabinowitz, Princeton University, Princeton, New Jersey
12:00 p.m12:15 p.m.	Discussion
12:15 p.m1:00 p.m. Grand Liberty Ballroom Moderator: Eileen O'Reilly, Mer	Debate: Targeting the Tumor vs. Stroma [CME Eligible] morial Sloan Kettering Cancer Center, New York, New York
Grand Liberty Ballroom Moderator: Eileen O'Reilly, Mer	
Grand Liberty Ballroom Moderator: Eileen O'Reilly, Mer	norial Sloan Kettering Cancer Center, New York, New York Stromal-epithelial co-evolution and complicity in pancreas cancer Sunil R. Hingorani, Fred & Pamela Buffett Cancer Center, Omaha,
Grand Liberty Ballroom Moderator: Eileen O'Reilly, Mer 12:15 p.m12:30 p.m.	norial Sloan Kettering Cancer Center, New York, New York Stromal-epithelial co-evolution and complicity in pancreas cancer Sunil R. Hingorani, Fred & Pamela Buffett Cancer Center, Omaha, Nebraska Targeting Tumor argument: Howard C. Crawford, Henry Ford Pancreatic